Physician profile
Kamran Khan
NPI 1164684007
$16,983.75
in general payments reported to CMS, 2019-2025
46 companies · $2,909 in 2025
The $2,909 reported for 2025 was more than what 82% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,713 · 2020: $1,023 · 2021: $1,606 · 2022: $3,289 · 2023: $3,231 · 2024: $3,212 · 2025: $2,909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,235 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,234.72 |
| Education | $117.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,076.73 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $2,811.77 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,245.27 | 2021-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $934.88 | 2019-2025 | Uptravi, Opsumit |
| Viiv Healthcare Company | $905.51 | 2022-2025 | Dovato, Cabenuva, Rukobia |
| Bard Access Systems, INC. | $898.06 | 2019 | |
| Genzyme Corporation | $856.68 | 2021-2025 | |
| Mylan Specialty L.P. | $814.90 | 2020-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $620.25 | 2019-2025 | Ofev, Spiriva Respimat, Jascayd |
| Merck Sharp & Dohme LLC | $610.50 | 2020-2025 | Winrevair, Dificid, Pifeltro |
| Grifols USA, LLC | $535.05 | 2019-2025 | Prolastin-C Liquid |
| Gilead Sciences, INC. | $377.67 | 2021-2025 | Veklury |
| United Therapeutics Corporation | $365.46 | 2021-2025 | Tyvaso, Tyvaso |
| Astellas Pharma US INC | $318.70 | 2021-2024 | Cresemba, Lexiscan |
| Amgen INC. | $270.06 | 2022-2025 | Tezspire |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $198.54 | 2021-2025 | Fetroja |
| Boston Scientific Corporation | $168.28 | 2022 | |
| Watermark Medical, INC. | $167.98 | 2021 | |
| Genentech USA, INC. | $151.59 | 2019-2023 | Xolair |
| Foundation Medicine, INC. | $148.30 | 2021 | |
| Baxter Healthcare | $146.20 | 2024-2025 | Hillrom - Volara System, Hillrom - Monarch Airway Clearance System |
| Abbott Laboratories | $125.00 | 2024 | Mitraclip |
| Electromed, INC. | $122.03 | 2024-2025 | Smartvest |
| Kiniksa Pharmaceuticals International, Plc | $117.89 | 2024 | Arcalyst |
| Novo Nordisk INC | $117.63 | 2020-2021 | |
| Napo Pharmaceuticals INC | $109.94 | 2023-2025 | Mytesi |
| La Jolla Pharmaceutical Company | $80.90 | 2022-2024 | Xacduro |
| Innovation Technologies INC | $80.57 | 2020 | |
| Viatris Specialty LLC | $80.56 | 2025 | Yupelri |
| Tactile Systems Technology INC | $74.48 | 2022-2024 | Entre Plus, Flexitouch Plus |
| Philips North America LLC | $57.98 | 2023-2025 | (8874) Incourage, Vest Therapy Und |
| Lilly USA, LLC | $49.24 | 2021-2025 | Zepbound |
| Janssen Biotech, INC. | $46.76 | 2023 | Symtuza |
| Aimmune Therapeutics, INC. | $39.24 | 2025 | Vowst |
| Pfizer INC. | $37.03 | 2023-2025 | |
| Smith+Nephew, INC. | $32.61 | 2022-2023 | Renasys Go V2 Home, Pico |
| Verona Pharma, INC. | $30.72 | 2025 | Ohtuvayre |
| Insmed, INC. | $28.66 | 2024 | Arikayce |
| Paratek Pharmaceuticals, INC. | $24.41 | 2021 | |
| Inspire Medical Systems, INC. | $22.96 | 2025 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $17.78 | 2022 | |
| Convatec INC. | $17.31 | 2022 | |
| Inogen, INC. | $13.74 | 2022 | |
| Abbvie INC. | $13.19 | 2022 | |
| Melinta Therapeutics, LLC | $12.90 | 2021 | |
| Medela LLC | $7.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kamran Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.